Filing Flows › Enovis (ENOV) › Guidance & outlook
Enovis (ENOV) guidance and outlook
Enovis (ENOV) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $2.3B–$2.4B for FY2026; Revenue +0.5% to +1% for FY2026; EBITDA $428M–$438M for FY2026; EPS $3.58–$3.79 for FY2026. Enovis' 10-Q filed Nov 5, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.3B–$2.4B | lowered |
| Revenue | FY2026 | +0.5% to +1% | lowered |
| EBITDA | FY2026 | $428M–$438M | raised |
| EPS | FY2026 | $3.58–$3.79 | raised |
| Free cash flow | FY2026 | +25% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- These statements are based on assumptions and assessments made by our management as of the filing of this Form 10-Q in light of their experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.
- Our ability to grow and our financial performance will be affected by our ability to address challenges and opportunities that are a consequence of expanding our global operations through our recent acquisitions, including efficiently utilizing our international sales channels, manufacturing and distribution capabilities, participating in the expansion of market opportunities, successfully completing global…
- Research and development expense increased compared to the prior year period due to an increase in new product development projects and activities and spending within our recently acquired businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies.
- We expect that our primary ongoing requirements for cash will be for working capital, capital expenditures, interest and principal repayments on our debt, strategic initiatives, restructuring outflows and other non-routine costs, and funding of acquisitions.
- The manner, timing and amount of any repurchases under the 2026 Share Repurchase Program will be determined by our management based on its evaluation of market conditions, stock price, liquidity, and other factors, and will be executed in accordance with applicable securities laws and regulations.
- Actual results may vary from what our management anticipates, and different assumptions or estimates about the future could have a material impact on our results of operations and financial position.
Enovis' latest quarter
Enovis, Q3 2026: revenue $559M (+2% year over year), operating margin 0.6%, net earnings $3.4M, operating cash flow $71.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Enovis raise or lower its guidance?
Enovis (ENOV) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $2.3B–$2.4B for FY2026; Revenue +0.5% to +1% for FY2026; EBITDA $428M–$438M for FY2026; EPS $3.58–$3.79 for FY2026.
What does Enovis expect?
These statements are based on assumptions and assessments made by our management as of the filing of this Form 10-Q in light of their experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Our ability to grow and our financial performance will be affected by our ability to address challenges and opportunities that are a consequence of expanding our global operations through our recent acquisitions, including efficiently utilizing our international sales channels, manufacturing and distribution capabilitie
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.